Assyro AI

Orange Book product · Brand (NDA)

EVZIO

NALOXONE HYDROCHLORIDE

Brand (NDA)NDA 205787DISCN KALEO INC

At a glance

Apr 03, 2014

Approved

Brand (NDA)

Application

Not listed

TE code

21

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 03, 2014

    12 yr 5 mo ago

  2. Patent 9278182 expires

    Listed drug product patent expiration.

    Feb 01, 2026

    5 mo ago

  3. Patent 8926594 expires

    Listed drug product patent expiration.

    Mar 31, 2026

    3 mo ago

  4. Patent 7731686 expires

    Listed drug product patent expiration.

    Jun 10, 2026

    9 d ago

  5. Today

  6. Patent 10960155 expires

    Listed drug product patent expiration.

    Jun 25, 2026

    in 6 d

  7. Patent 11590286 expires

    Listed drug product patent expiration.

    Dec 12, 2026

    in 6 mo

  8. Patent 9238108 expires

    Listed drug product patent expiration.

    Feb 20, 2027

    in 8 mo

  9. Patent 8206360 expires

    Listed drug product patent expiration.

    Feb 27, 2027

    in 8 mo

  10. Patent 9724471 expires

    Listed drug product patent expiration.

    May 23, 2027

    in 11 mo

  11. Patent 7947017 expires

    Listed drug product patent expiration.

    Mar 12, 2028

    in 1 yr 9 mo

  12. Patent 7749194 expires

    Listed drug product patent expiration.

    Oct 30, 2028

    in 2 yr 5 mo

  13. Patent 8231573 expires

    Listed drug product patent expiration.

    Nov 25, 2028

    in 2 yr 6 mo

  14. Patent 8226610 expires

    Listed drug product patent expiration.

    Apr 10, 2029

    in 2 yr 10 mo

  15. Patent 8021344 expires

    Listed drug product patent expiration.

    Nov 02, 2029

    in 3 yr 5 mo

  16. Patent 10322239 expires

    Listed method-of-use patent (U-1907) expiration.

    Feb 28, 2031

    in 4 yr 9 mo

  17. Patent 8939943 expires

    Listed drug product patent expiration.

    Feb 28, 2031

    in 4 yr 9 mo

  18. Patent 9022022 expires

    Listed drug product patent expiration.

    Feb 28, 2031

    in 4 yr 9 mo

  19. Patent 9474869 expires

    Listed drug product patent expiration.

    Feb 28, 2031

    in 4 yr 9 mo

  20. Patent 10143972 expires

    Listed method-of-use patent (U-2476) expiration.

    May 24, 2031

    in 5 yr

  21. Patent 8627816 expires

    Listed drug product patent expiration.

    Feb 04, 2032

    in 5 yr 9 mo

  22. Patent 9517307 expires

    Listed drug product patent expiration.

    Jul 18, 2034

    in 8 yr 2 mo

  23. Patent 10220158 expires

    Listed drug product patent expiration.

    Mar 20, 2035

    in 8 yr 11 mo

Pharmaceutical detail

Active ingredient

NALOXONE HYDROCHLORIDE

Strength

0.4MG/0.4ML (0.4MG/0.4ML)

Dosage form

SOLUTION

Route

INTRAMUSCULAR, SUBCUTANEOUS

TE code

Not listed

Application

NDA 205787

Product number

001

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (21)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9278182Feb 01, 20265 mo ago
Product
8926594Mar 31, 20263 mo ago
Product
7731686Jun 10, 20269 d ago
Product
10960155Jun 25, 2026in 6 d
Product
11590286Dec 12, 2026in 6 mo
Product
9238108Feb 20, 2027in 8 mo
Product
8206360Feb 27, 2027in 8 mo
Product
9724471May 23, 2027in 11 mo
ProductU-2092
7947017Mar 12, 2028in 1 yr 9 mo
Product
7749194Oct 30, 2028in 2 yr 5 mo
Product
8231573Nov 25, 2028in 2 yr 6 mo
Product
8226610Apr 10, 2029in 2 yr 10 mo
Product
8021344Nov 02, 2029in 3 yr 5 mo
Product
10322239Feb 28, 2031in 4 yr 9 mo
U-1907
8939943Feb 28, 2031in 4 yr 9 mo
Product
9022022Feb 28, 2031in 4 yr 9 mo
Product
9474869Feb 28, 2031in 4 yr 9 mo
ProductU-1907
10143972May 24, 2031in 5 yr
U-2476
8627816Feb 04, 2032in 5 yr 9 mo
Product
9517307Jul 18, 2034in 8 yr 2 mo
ProductU-1925
10220158Mar 20, 2035in 8 yr 11 mo
ProductU-2500
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.